Drug Trial Radar · NCT04020055
A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease
Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
14
Planned (sponsor's estimate)
Start
Oct 31, 2022
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Amicus TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 15, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects with Fabry Disease and Amenable GLA Variants and Severe Renal Impairment (SRI) or End Stage Renal Disease (ESRD)
Conditions
- Fabry Disease
Interventions
migalastat HCl 150 mgDrug
migalastat HCl 150 mg capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed concentration (Cmax)Time frame: Baseline through Month 12
- Time to maximum concentration (tmax)Time frame: Baseline through Month 12
- Apparent terminal elimination half-life (t½)Time frame: Baseline through Month 12
- Concentration at the end of a dosing interval at steady state (Ctrough)Time frame: Baseline through Month 12
- Average plasma migalastat concentration over the dosing interval (Cavg)Time frame: Baseline through Month 12
- Area under the concentration-time curve at steady state during the dosing interval (AUC0-τ)Time frame: Baseline through Month 12
- Area under the concentration-time curve from zero time (pre-dose) extrapolated to infinite time (AUC0-∞)Time frame: Baseline through Month 12
- Apparent plasma clearance (CL/F)Time frame: Baseline through Month 12
- Apparent terminal phase volume of distribution (Vz/F)Time frame: Baseline through Month 12
- Dialysis clearance (CLD)Time frame: Baseline through Month 12
- Volume of dialysate collected during the interval (VD)Time frame: Baseline through Month 12
- Mean migalastat concentration in dialysate (CD)Time frame: Baseline through Month 12
- Amount recovered in dialysate (AeD)Time frame: Baseline through Month 12
- Fraction of the dose recovered in dialysate (FeD)Time frame: Baseline through Month 12
- Mean migalastat plasma concentration during the dialysis interval (P)Time frame: Baseline through Month 12
- Mean inlet area under the curve (AUCinlet)Time frame: Baseline through Month 12
- Mean outlet area under the curve (AUCoutlet)Time frame: Baseline through Month 12
- Extraction ratio (ED)Time frame: Baseline through Month 12
- Dialyzer blood flow (QD)Time frame: Baseline through Month 12
- Cumulative amount excreted over all collection intervals (Ae0-τ)Time frame: Baseline through Month 12
- Fraction of the dose recovered after the last measurable time point postdose (Fe0-τ)Time frame: Baseline through Month 12
- Renal clearance (CLr)Time frame: Baseline through Month 12
Locations
12 sites in 6 countries. Site status is shown where the registry gives one.
Emory University
Atlanta, Georgia
The Cleveland Clinic
Cleveland, Ohio
Lysosomal and Rare Disorders Research and Treatment Center, Inc
Fairfax, Virginia
Royal Melbourne Hospital
Parkville, Victoria, Australia
Royal Perth Hospital
Perth, Washington, Australia
Osaka University Hospital
Suita, Osaka, Japan
Shizuoka General Hospital
Shizuoka, Shizuoka, Japan
Centro Hospitalar e Universitário de Coimbra (CHUC)
Coimbra, Portugal
Hospital Universitari(o) de Bellvitge (HUB) Feixa Llarga
Barcelona, Spain
Hospital General Universitario de Elda
Elda, Spain
Hospital General Universitario Gregorio Marañon
Madrid, Spain
Salford Royal Hospital
Salford, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.